Replies to post #692473 on NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

Thanks, Astavakra, for your kind correction based on excellent DD! The CHM meeting is where advisers decide how to advise the MHRA about approvals. So decisions on approval will likely lag behind the CHM meeting dates I gave in my former posts.

From Astavakra's DD: from ChatGBT:

In the UK, the Commission on Human Medicines (CHM) is responsible for advising the Medicines and Healthcare products Regulatory Agency (MHRA) on matters relating to the safety, efficacy, and quality of medicines. One of the key responsibilities of the CHM is to make recommendations regarding Marketing Authorisation Applications (MAAs) for new medicines.